West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company's latest quarterly dividend payment.
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical beats Q4 EPS and revenue estimates as proprietary products drive growth, while shares jump nearly 3.6% premarket on upbeat 2026 outlook.
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.82 per share a year ago.
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.
West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical (WST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously bounced significantly.
West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support.
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).